HBSP (USA)
-
BeiGene
Shih, Willy; Zhang, JimmyCase HBS-618033-EStrategyBeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeStarting at €8.20
-
BeiGene, PowerPoint Supplement
Shih, Willy; Zhang, JimmyCase HBS-618043-EStrategyPowerPoint slides for case 618033.Starting at €8.20
-
China Yintai: Developing Shared Value in China
Marquis, Christopher; Zhang, Ying; Yang, ShiyuCase HBS-415078-EUnder the leadership of CEO and President Shen Guojun, China Yintai was increasingly committed to philanthropic initiatives. Drawing upon his experience as an entrepreneur and a philanthropist, Mr. Shen saw the urgent need to build bridges between business practices and philanthropy and cultivate a new business culture that incorporated "shared value." The case study documents Yintai's recent collaboration with Peking University on founding China...Starting at €8.20
-
BeiGene, Teaching Note
Shih, Willy; Zhang, JimmyTeaching Note HBS-618039-EStrategyTeaching Note for 618033 BeiGene. BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window of opportunity to develop drug candidates toward known targets with known mechanisms of actions that would allow it to become first-in-class in Ch...Starting at €0.00